Elevance Health, Inc.

  • Earnings Score
  • Moat Score
  • Safety Score
  • Final Score
  • Market Cap $93.52B
  • PE 16
  • Debt $29.75B
  • Cash $7.50B
  • EV $115.77B
  • FCF $3.67B

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$5.91B
EBIT$8.06B
ROE14%
ROA7%
FCF$3.67B
Equity$42.62B
Growth Stability99%
PE15.83
PEG2.85
PB2.19
P/FCF25.45
P/S0.51
Price/Cash0.08
Debt/Equity0.7
Debt/FCF8.1
Net Margins4%
Gross Margins89%
Op. Margins4%
Earnings CAGR11%
Sales Growth YoY15%
Sales Growth QoQ8%
Sales CAGR11%
FCF CAGR6%
Equity CAGR7%
Earnings Stability0.81
Earnings Growth YoY-3%
Earnings Growth QoQ429%
Earnings CAGR 5Y6%
Sales CAGR 5Y11%
FCF CAGR 5Y-27%
Equity CAGR 5Y6%
Earnings CAGR 3Y7%
Sales CAGR 3Y7%
FCF CAGR 3Y-49%
Equity CAGR 3Y8%
Market Cap$93.52B
Revenue$183.33B
Dividend Yield2%
Payout Ratio26%
Assets$119.72B
Total Debt$29.75B
Cash$7.50B
Shares Outstanding225.64M
EV115.77B
Earnings Score92%
Moat Score83%
Safety Score79%
Final Score85%
Working Capital18.42B
Current Ratio1.43
Gross Profit$162.42B
Shares Growth 3y-2%
Equity Growth QoQ3%
Equity Growth YoY5%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Elevance Health (formerly known as Anthem) remains one of the leading health insurers in the U.S., providing medical benefits to roughly 45 million medical members. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid, too.

SEC Filings

Direct access to Elevance Health, Inc. (ELV) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 31
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Elevance Health, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Elevance Health, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 11%
Stability 81%
loading chart...

Elevance Health, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Elevance Health, Inc..

= $54B
012345678910TV
fcf$3.7B$3.9B$4.1B$4.3B$4.6B$4.8B$5.1B$5.4B$5.7B$6B$6.3B$63B
DCF$3.5B$3.4B$3.2B$3.1B$3B$2.9B$2.8B$2.6B$2.5B$2.4B$24B
Value$54B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins3%3%4%4%5%4%4%4%3%3%4%
ROA-8%7%8%9%8%9%8%8%7%7%
ROE-10%14%13%15%14%17%17%15%14%14%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-6.195.897.344.212.143.353.53.927.148.1
Debt over Equity0.690.650.750.670.660.620.670.70.670.780.7
Growth Stability---100%100%100%100%100%100%99%99%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-7%6%2%13%17%14%13%9%3%11%
Earnings YoY growth--4%56%-2%28%-5%33%-1%-1%-0%6%
Equity YoY growth-9%6%8%11%5%9%1%8%5%6%
FCF YoY growth--25%29%-23%90%94%-25%-0%-7%-33%-27%